Sugi Predict

Sugi Predict / Compounds / SCHEMBL2174744

SCHEMBL2174744

SCHEMBL2174744

NC(=O)c1ccc2c(Cl)ccnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMYD3 Q9H7B4 1/20 0.48
▸ CSNK2A2 P19784 2/20 0.44
▸ CSNK2B P67870 2/20 0.44
▸ MAP4K4 O95819 3/20 0.43
▸ CSNK2A1 P68400 3/20 0.43
▸ HIPK2 Q9H2X6 2/20 0.43
▸ MKNK2 Q9HBH9 2/20 0.43
▸ PIM1 P11309 2/20 0.43
▸ PIM2 Q9P1W9 2/20 0.43
▸ CDC7 O00311 1/20 0.43
▸ PLK4 O00444 1/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ PDPK1 O15530 1/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ DYRK3 O43781 1/20 0.43
▸ ROCK2 O75116 1/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ PRKCG P05129 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7230935 0.87 MAP4K4 (0.43) SMYD3MAP4K4CSNK2A1HIPK2MKNK2
SCHEMBL1732368 0.85 SMYD3 (0.49) SMYD3CSNK2A2CSNK2BCSNK2A1MAPKAPK2
SCHEMBL22972267 0.85 SMYD3 (0.49) SMYD3HIPK2NR4A2SOS2KDM4E
SCHEMBL8600739 0.83 SMYD3 (0.51) SMYD3KDM4ETDP1MAPTMEN1
SCHEMBL22972033 0.83 SMYD3 (0.48) SMYD3NR4A2KDM4ETDP1MAPT
SCHEMBL5522936 0.81 NR4A2 (0.54) SMYD3CSNK2A2CSNK2BCSNK2A1HIPK2
SCHEMBL18496671 0.80 CSNK2A1 (0.52) CSNK2A2CSNK2BMAP4K4CSNK2A1HIPK2
SCHEMBL4399984 0.80 ALOX15 (0.52) SMYD3CSNK2A2CSNK2BCSNK2A1AXL
SCHEMBL30426250 0.80 ALOX15 (0.52) SMYD3CSNK2A2CSNK2BCSNK2A1AXL
SCHEMBL2173115 0.80 PLK1 (0.52) SMYD3CDK8ACVR1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010330-B1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS HIRUNDO BIOSCIENCES (BE) 2025-10-01 — — EP disclosed
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 — — US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 — — CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 — — EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 — — WO disclosed
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2022-12-08 — — US disclosed
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2022-12-08 — — US disclosed
EP-4010330-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. Pharma (BE) 2022-06-15 — — EP disclosed
CN-114391009-A Quinoline derivatives as protein kinase inhibitors BCI制药公司 2022-04-22 — — CN disclosed
WO-2021023888-A1 ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2021-02-11 — — WO disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 — — US disclosed
EP-1994025-A1 QUINOLINE DERIVATIVES AstraZeneca AB (SE) 2008-11-26 — — EP disclosed
WO-2007099326-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 — — US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 — — US disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 — — WO disclosed
EP-1140849-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 — — EP disclosed
WO-2000040560-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 — — WO disclosed
US-5773449-A BACTERICIDES FOR HELICOBACTER ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 1998-06-30 — — US disclosed
EP-0786454-A1 THIOQUINOLONE DERIVATIVE ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 1997-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABL1, PHKB, EEF2K SMYD3 2725/4885CSNK2A2 95/4885CSNK2B 37/4885
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 SMYD3 2078/4885CSNK2A2 794/4885CSNK2B 699/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 SMYD3 1752/4885CSNK2A2 591/4885CSNK2B 585/4885
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 SMYD3 2835/4885CSNK2A2 394/4885CSNK2B 421/4885
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 SMYD3 2828/4885CSNK2A2 471/4885CSNK2B 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.